@ahmadyasinmd's MK-677 muscle claims, fact-checked

What did @ahmadyasinmd actually say?

The creator, who identifies as "Dr. Jassen" in the transcript (though the account is @ahmadyasinmd), describes MK-677 as a peptide that will give you "insane muscles" and calls it a "potent growth hormone" secretagogue. He claims it stimulates growth hormone release through a pathway separate from GHRH, is taken orally in pill or liquid form at 10 to 25 milligrams per day, and is cycled 2 to 3 months on with 1 to 2 months off. He lists benefits including lean muscle mass, bone density, reversal of muscle wasting, improved REM sleep, and a "nootropic effect that boosts memory and cognition." He flags two side effects: intense hunger that wakes you at night and lower-extremity swelling. He ends with a disclaimer to consult a doctor before using peptides.

Does the science back this up?

Some of it, yes, but the confidence in the claims outpaces what the research actually supports. MK-677 is real, the mechanism is real, and a few of the benefits have legitimate study backing. The muscle and sleep claims are the strongest. The memory and cognition claim is the weakest.

MK-677 is technically not a peptide. It is a non-peptide small molecule that mimics ghrelin and activates the growth hormone secretagogue receptor (GHSR). That is a meaningful distinction the creator skips entirely. On mechanism, he is correct that it works through a different pathway than GHRH agonists like CJC-1295.

The muscle and body composition claims have some research support. Nass et al. (2008, Annals of Internal Medicine) found that MK-677 increased lean body mass in older adults over two years, though muscle strength improvements were not significant. Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed GH and IGF-1 increases with MK-677 administration. On sleep, Copinschi et al. (1997, Sleep) found MK-677 increased REM sleep and sleep quality in young and older adults, which is one of the more replicated findings. The cognition claim is largely extrapolated from IGF-1's neuroprotective associations, not direct MK-677 memory trials in healthy humans.

What did they get wrong (or right)?

The "insane muscles" opening is marketing, not medicine, and it sets a misleading tone. The actual study data shows modest lean mass improvements, not dramatic transformation.

The creator gets the mechanism roughly right. Acting on pituitary and hypothalamic receptors via the ghrelin receptor pathway is accurate. Saying it uses "a different pathway than growth hormone releasing hormone" is correct and useful context.

He is also right that hunger disruption is the most notable side effect. The technical term is increased appetite driven by ghrelin receptor activation, and it is well-documented. Calling it making you "wake up and dig in your fridge" is colorful but captures something real.

What he gets wrong or incomplete: MK-677 is not a peptide, and calling it one is factually incorrect. More importantly, the side effect list stops too early. Sustained elevation of GH and IGF-1 raises concerns about insulin resistance, with Nass et al. (2008) noting increased fasting glucose and insulin resistance in the treatment group. Water retention and edema are also well-reported. Long-term safety data in healthy adults is limited, and the creator's framing that the only notable side effects are hunger and some leg swelling undersells that gap significantly. The "no known injectable version" claim is also incorrect. Injectable MK-677 formulations have been documented in research and compounding contexts, though oral is the most common form used clinically.

What should you actually know?

MK-677 is not approved by the FDA for any indication. It has been studied in clinical trials for conditions like muscle wasting, growth hormone deficiency, and hip fracture recovery, but it has not cleared the regulatory bar for any of them. That is not a minor footnote.

The dosing range the creator mentions, 10 to 25 mg daily, tracks with what has been used in clinical trials, but it is not a green light. The cycling protocol he describes (2 to 3 months on, 1 to 2 months off) is empirical convention in the optimization community, not something validated in controlled trials.

The hunger side effect is genuinely significant for anyone tracking caloric intake or managing metabolic health. Ghrelin receptor activation can meaningfully increase caloric consumption, which may partially offset any body composition benefits. People with pre-existing insulin resistance or elevated fasting glucose should know that sustained IGF-1 elevation may worsen those markers, based on Nass et al. (2008).

If MK-677 interests you clinically, the conversation to have with a provider is not just "can I take this" but "do I have a documented GH deficiency or clinical indication, and what are my baseline metabolic markers." The current research base, while promising in some areas, does not support casual self-administration for body composition goals in otherwise healthy adults.